Phase II study of S-1 for relapsed or refractory thymoma or thymic carcinoma
- Conditions
- Thymoma/Thymic carcinoma
- Registration Number
- JPRN-UMIN000008174
- Lead Sponsor
- orth Japan Lung Cancer Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Not provided
1. Serious uncontrolled infections or body temperature higher than 38 degree centigrade 2. Continuous administration of an oral steroid or an immunosuppressive agent 3. With severe concurrent disease 4. Symptomatic brain metastasis 5. With malignant pleural, peritoneal effusion requiring drainage or pericardial effusion 6. With severe drug allergies 7. Contraindication with S-1 8. Previous treatment with fluoropyrimidines such as S-1, UFT 9. Current use of flucytosine 10. With interstitial pneumonitis or pulmonary fibrosis detectable on chest X-ray 11. Lactating, pregnant or possibly pregnant women, or those willing to become pregnant 12. Physician concludes that the patient's participation in this trial is inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method